Cyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing?

Authors :: Wilton T
Source :: Emergency medicine Australasia : EMA [Emerg Med Australas] 2004 Feb; Vol. 16 (1), pp. 65-73.
Publication Year :: 2004
Abstract: Cyclooxygenase-2 selective inhibitors (COXIB or CSI) have been released with a fanfare as efficacious and safer alternatives to traditional non-steroidal anti-inflammatory drugs. They purport to offer equivalent degrees of analgesia and an improved safety profile. COXIB currently available in Australasia are celecoxib (Celebrex), rofecoxib (Vioxx) and etoricoxib (Arcoxia). This review discusses the pharmacology of these agents and reviews recent literature regarding their effectiveness and safety. It endeavours to answer the question 'Should we be using COXIB in emergency departments in Australasia'?

Subjects :: Alzheimer Disease drug therapy
Anti-Inflammatory Agents, Non-Steroidal metabolism
Anti-Inflammatory Agents, Non-Steroidal pharmacology
Arachidonic Acid immunology
Arachidonic Acid metabolism
Australasia
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors metabolism
Cyclooxygenase Inhibitors pharmacology
Drug Interactions
Drug Utilization standards
Drug-Related Side Effects and Adverse Reactions
Evidence-Based Medicine
Female
Gastrointestinal Hemorrhage chemically induced
Humans
Inflammation
Kidney Diseases chemically induced
Membrane Proteins
Neoplasms drug therapy
Pain drug therapy
Patient Selection
Pregnancy
Prostaglandin-Endoperoxide Synthases
Safety
Tocolysis methods
Treatment Outcome
Anti-Inflammatory Agents, Non-Steroidal therapeutic use
Cyclooxygenase Inhibitors therapeutic use
Drug Prescriptions standards
Drug Therapy methods
Drug Therapy standards
Emergency Treatment adverse effects
Emergency Treatment methods
Emergency Treatment standards
Isoenzymes antagonists & inhibitors
Practice Patterns, Physicians' standards

Full Text Access

Tools